<DOC>
	<DOCNO>NCT01133678</DOCNO>
	<brief_summary>Primary Compare response rate induction chemotherapy consist cisplatin/paclitaxel/cetuximab +/- everolimus . Secondary Determine maximum administer dose ( MAD ) , maximum tolerate dose ( MTD ) , dose limit toxicity ( DLT ) , safety everolimus cisplatin/paclitaxel/cetuximab induction chemotherapy .</brief_summary>
	<brief_title>Study Locally Advanced Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Treatment naïve stage III ( hypopharynx , nasopharynx primary ) stage IVa/IVb ( site ) histologically proven SCCHN definitive evidence metastatic disease Patients unknown primary site tumor histologically proven squamous cell carcinoma cervical lymph node felt arise site head neck eligible Patients must least one measurable site disease accord RECIST criterion Age ≥ 18 year Karnofsky performance status &gt; 70 % Adequate bone marrow function show : ANC ≥ 1.5 x 109/L , Platelets ≥ 100 x 109/L , Hb &gt; 9 g/dL Adequate liver function show : Serum bilirubin ≤ 1.5 x ULN ALT AST ≤ 2.5x ULN INR PTT ≤1.5 . ( Anticoagulation allow target INR ≤ 1.5 stable dose warfarin stable dose LMW heparin &gt; 2 week time randomization . ) Adequate renal function : serum creatinine ≤ 1.5 x ULN Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication . Signed informed consent Patients currently receive anticancer therapy receive anticancer therapy within 4 week start study drug ( include chemotherapy , radiation therapy , antibody base therapy , etc . ) Patients , major surgery [ define require general anesthesia include tonsillectomy , neck dissection , panendoscopy ( triple endoscopy examination general anesthesia ) ] , significant traumatic injury within 4 week start study drug ; patient recover side effect major surgery ; patient may require major surgery course study Prior treatment investigational drug within precede 4 week Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent . Topical inhale corticosteroid allow . Patients receive immunization attenuate live vaccine within one week study entry study period Unequivocal demonstration metastatic disease ( i.e . M1 disease ) . Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin . Patients severe and/or uncontrolled medical condition condition could affect participation study : Symptomatic congestive heart failure New York heart Association Class III IV Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within 6 month start study drug , serious uncontrolled cardiac arrhythmia clinically significant cardiac disease Severely impaired lung function define spirometry DLCO 50 % normal predict value and/or 02 saturation 88 % less rest room air Uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN Active ( acute chronic ) uncontrolled severe infection Liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis A known history HIV seropositivity Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) Nota bene : subject require administration everolimus feed tube allow participate Patients active , bleed diathesis Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . If barrier contraceptive use , must continue throughout trial sex . Hormonal contraceptives acceptable sole method contraception . ( Women childbearing potential must negative urine serum pregnancy test within 7 day prior administration everolimus ) Patients receive prior treatment mTOR inhibitor SCCHN ( sirolimus , temsirolimus , everolimus ) . Patients know hypersensitivity everolimus ( everolimus ) rapamycins ( sirolimus , temsirolimus ) excipients Patients know hypersensitivity cetuximab , cremaphor , paclitaxel , carboplatin , 5FU , hydroxyurea , compound similar chemical biologic composition History noncompliance medical regimen Patients unwilling unable comply protocol Baseline neurologic deficit ( &gt; grade II neuropathy ) Prior severe infusion reaction ( grade 4 ) monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Squamous Cell Carcinoma</keyword>
</DOC>